Autopsy report · NCT05269355
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Cause of deathFunding or business
“Business decision”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 2 months before it stopped.
- 359 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- PTC Therapeutics
- Sponsor type
- Industry
- Conditions
- Leiomyosarcoma
- Interventions
- Unesbulin; Dacarbazine; Placebo
- Participants
- 359
- Sites
- 54
- Countries
- Australia, Brazil, Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.